Our results indicated that the serum level of TGFα was elevated in chemoresistant patients during and after the NACT treatment but not in chemosensitive patients or the entire cohort of HNSCC patients (Fig. 4j). This evidence concerns the gene TGFA and head and neck squamous cell carcinoma.